aptose
present
oppenheimer
fall
healthcare
life
sciences
medtech
summit
san
diego
toronto
globe
newswire
aptose
biosciences
nasdaq
apto
tsx
aps
company
developing
highly
differentiated
therapeutics
target
underlying
mechanisms
cancer
today
announced
william
rice
chairman
president
chief
executive
officer
aptose
management
team
participate
oppenheimer
fall
healthcare
life
sciences
medtech
summit
oppenheimer
fall
healthcare
life
sciences
medtech
summit
date
tuesday
september
time
pm
edt
format
fireside
chat
matthew
biegler
senior
analyst
oppenheimer
webcast
link
audio
webcast
also
accessed
aptose
website
archived
shortly
live
events
aptose
aptose
biosciences
biotechnology
company
committed
developing
personalized
therapies
addressing
unmet
medical
needs
oncology
initial
focus
hematology
company
small
molecule
cancer
therapeutics
pipeline
includes
products
designed
provide
single
agent
efficacy
enhance
efficacy
therapies
regimens
without
overlapping
toxicities
company
two
investigational
products
hematologic
malignancies
oral
btk
kinase
inhibitor
phase
trial
patients
relapsed
refractory
b
cell
malignancies
including
chronic
lymphocytic
leukemia
cll
small
lymphocytic
lymphoma
sll
lymphoma
nhl
failed
intolerant
standard
therapies
received
ind
allowance
conduct
separate
phase
trial
patients
relapsed
refractory
acute
myeloid
leukemia
aml
clinical
stage
agent
directly
targets
myc
oncogene
suppresses
expression
phase
clinical
trial
treatment
patients
relapsed
refractory
acute
myeloid
leukemia
aml
high
risk
myelodysplastic
syndrome
mds
information
please
visit
information
please
contact
